PMID- 38022592 OWN - NLM STAT- MEDLINE DCOM- 20231201 LR - 20240401 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Molecular and cellular characterization of immunity conferred by lactobacilli against necrotic enteritis in chickens. PG - 1301980 LID - 10.3389/fimmu.2023.1301980 [doi] LID - 1301980 AB - Necrotic enteritis is an important enteric disease of poultry that can be controlled with in-feed antibiotics. However, with the concerns over antimicrobial resistance, there is an increased interest in the use of alternatives. Probiotics are one of the alternatives that have gained considerable attention due to their antimicrobial and immunomodulatory activities. Therefore, in the present study, we evaluated the effects of two different Lactobacillus species alone or as a cocktail on prevention of necrotic enteritis. Day-old male broiler chickens were divided into five groups and on days 1, 8, 15, and 22, birds in groups 2 and 3 received 1x10(8) colony forming units (CFU) of L. johnsonii and L. reuteri, respectively. Group 4 received probiotic cocktails containing both bacteria (10(8) CFU/bird) and the negative and positive control groups did not receive any lactobacilli. Starting on day 23 post-hatch, birds in all groups (except the negative control group) were orally challenged twice per day with 3x10(8) CFU of a pathogenic C. perfringens strain for 3 days. Tissue and cecal samples were collected before and after challenge to assess gene expression, lymphocyte subsets determination, and microbiome analysis. On day 26 of age, lesion scoring was performed. The results demonstrated that the group that received the lactobacilli cocktail had significantly reduced lesion scores compared to the positive control group. In addition, the expression of interleukin (IL)-12 in the jejunum and CXC motif chemokine ligand 8 (CXCL8), IL-13, and IL-17 in the ileum were downregulated in the group that received the lactobacilli cocktail when compared to the positive control. Treating chickens with the lactobacilli cocktail prior to challenge enhanced the percentage of CD3(-)CD8(+) cells and Bu-1(+)IgY(+) B cells in the ileum and increased the frequency of monocyte/macrophages, CD3(-)CD8(+) cells, Bu-1(+)IgM(+), and Bu-1(+)IgY(+) B cells in the jejunum. Treatment with the lactobacilli cocktail reduced the relative expression of Gamma-Protobacteria and Firmicutes compared to the positive control group. In conclusion, the results presented here suggest that treatment with the lactobacilli cocktail containing L. johnsonii and L. reuteri reduced necrotic enteritis lesions in the small intestine of chickens, possibly through the modulation of immune responses. CI - Copyright (c) 2023 Alizadeh, Shojadoost, Boodhoo, Raj and Sharif. FAU - Alizadeh, Mohammadali AU - Alizadeh M AD - Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada. FAU - Shojadoost, Bahram AU - Shojadoost B AD - Ceva Animal Health Inc., Guelph, ON, Canada. FAU - Boodhoo, Nitish AU - Boodhoo N AD - Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada. FAU - Raj, Sugandha AU - Raj S AD - Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada. FAU - Sharif, Shayan AU - Sharif S AD - Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231107 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Animals MH - Male MH - *Clostridium Infections/prevention & control/veterinary/microbiology MH - *Enteritis/prevention & control/veterinary/microbiology MH - Chickens/microbiology MH - Lactobacillus MH - Clostridium perfringens/physiology MH - Anti-Bacterial Agents PMC - PMC10662302 OTO - NOTNLM OT - chicken OT - cytokine OT - lactobacilli OT - lymphocyte OT - microbiome OT - necrotic enteritis COIS- Author BS was employed by the company "CEVA Animal Health". The remaining authors declare that the research was conducted in the absence of any commercial of financial relationship that could be construed as potential conflict of interest. EDAT- 2023/11/29 18:41 MHDA- 2023/12/01 06:45 PMCR- 2023/01/01 CRDT- 2023/11/29 15:27 PHST- 2023/09/25 00:00 [received] PHST- 2023/10/23 00:00 [accepted] PHST- 2023/12/01 06:45 [medline] PHST- 2023/11/29 18:41 [pubmed] PHST- 2023/11/29 15:27 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1301980 [doi] PST - epublish SO - Front Immunol. 2023 Nov 7;14:1301980. doi: 10.3389/fimmu.2023.1301980. eCollection 2023.